Evidence map›Paper›PMID 37267601›Full record

ArticleChronic obstructive pulmonary diseases (Miami, Fla.)2023

Associations of Smoking, Cytomegalovirus Serostatus, and Natural Killer Cell Phenotypes in Smokers With and At Risk for COPD.

Robert M Burkes, Elijah Bailey, Timothy Hwalek, Andrew Osterburg, Laura Lach, Ralph Panos, Stephen N Waggoner, Michael T Borchers

Open access · diamondAbstract read
In one paragraph

Article in Chronic obstructive pulmonary diseases (Miami, Fla.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Robert M BurkesDivision of Pulmonary, Critical Care and Sleep Medicine, College of Medicine, University of Cincinnati, Cincinnati, Ohio, United States.
Elijah BaileyDivision of Pulmonary, Critical Care and Sleep Medicine, College of Medicine, University of Cincinnati, Cincinnati, Ohio, United States.
Timothy HwalekDivision of Pulmonary, Critical Care and Sleep Medicine, College of Medicine, University of Cincinnati, Cincinnati, Ohio, United States.
Andrew OsterburgDivision of Pulmonary, Critical Care and Sleep Medicine, College of Medicine, University of Cincinnati, Cincinnati, Ohio, United States.
Laura LachDepartment of Veterans Affairs, Cincinnati VA Hospital, Cincinnati, Ohio, United States.
Ralph PanosDepartment of Veterans Affairs, Cincinnati VA Hospital, Cincinnati, Ohio, United States.
Stephen N WaggonerCenter for Autoimmune Genomics and Etiology, Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States.
Michael T BorchersDivision of Pulmonary, Critical Care and Sleep Medicine, College of Medicine, University of Cincinnati, Cincinnati, Ohio, United States.
Cincinnati VA Medical Center · USUniversity of Cincinnati · USCincinnati Children's Hospital Medical Center · US

Funding

LCenter for Clinical and Translational Science and TrainingUL1TR001425 · NCATS · UNIVERSITY OF CINCINNATI · PI HEUBI, JAMES E., KISSELA, BRETT M · 2015 to 2024
$37.5M
Molecular and Cellular Pathogenesis of Pulmonary Langerhans Cell HistiocytosisR01HL162662 · NHLBI · UNIVERSITY OF CINCINNATI · PI Michael Borchers · 2023 to 2026
$2.2M
Natural Killer Cell Functions in COPDI01BX002347 · VA · CINCINNATI VA MEDICAL CENTER RESEARCH · PI BORCHERS, MICHAEL · 2015 to 2018
–
Natural Killer Cell Subpopulations in COPD ExacerbationsI01CX001891 · VA · CINCINNATI VA MEDICAL CENTER RESEARCH · PI BORCHERS, MICHAEL · 2021 to 2024
–
BLRD VA I01 BX002347CSRD VA I01 CX001891NCATS NIH HHS UL1 TR001425NHLBI NIH HHS R01 HL162662NIH HHS HL119538NIH HHS UL1TR001425
6 · The paper itself

Abstract

Introduction: Chronic obstructive disease (COPD) risk factors, smoking, and chronic infection (cytomegalovirus [CMV]) may mold natural killer (NK) cell populations. What is not known is the magnitude of the effect CMV seropositivity imparts on populations of smokers with and at risk for COPD. We investigate the independent influence of CMV seropositivity on NK cell populations and differential effects when stratifying by COPD and degree of smoking history. Methods: Descriptive statistics determine the relationship between cytotoxic NK cell populations and demographic and clinical variables. Multivariable linear regression and predictive modeling were performed to determine associations between positive CMV serology and proportions of CD57+ and natural killer group 2C (NKG2C)+ NK cells. We dichotomized our analysis by those with a heavy smoking history and COPD and described the effect size of CMV seropositivity on NK cell populations. Results: When controlled for age, race, sex, pack-years smoked, body mass index, and lung function, CMV+ serostatus was independently associated with a higher proportion of CD57+, NKG2C+, and NKG2C+CD57+ NK cells. CMV+ serostatus was the sole predictor of larger NKG2C+ and CD57+NKG2C+ populations. Associations are more pronounced in those with COPD and heavy smokers. Conclusions: Among Veterans who are current and former smokers, CMV+ serostatus was independently associated with larger CD57+ and NKG2C+ populations, with a larger effect in heavy smokers and those with COPD, and was the sole predictor for increased expression of NKG2C+ and CD57+NKG2C+ populations. These findings may be broadened to include the assessment of longitudinal NK cell population change, accrued inflammatory potential, and further identification of pro-inflammatory NK cell population clusters.

Indexed as

COPDcytomegalovirusnatural killer cell phenotypessmoking

Identifiers

PMID37267601
PMCPMC10484488
OpenAlexW4379184978

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.